相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks et al.
NATURE (2022)
Current treatment options for HER2-positive breast cancer patients with brain metastases
Daniele Galanti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
Maxime Jullien et al.
CELLS (2020)
BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
Tamara Vervloessem et al.
CELL DEATH & DISEASE (2020)
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Chikezie O. Madu et al.
JOURNAL OF CANCER (2020)
The chick embryo chorioallantoic membrane as an in vivo experimental model to study human neuroblastoma
Domenico Ribatti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Evaluating the effect of Avastin on breast cancer angiogenesis using synchrotron radiation
Shengmei Gu et al.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY (2019)
Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling
Tamara Vervloessem et al.
CELL CALCIUM (2018)
Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway
Yoshiro Itatani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Sulforaphane Rescues Ethanol-Suppressed Angiogenesis through Oxidative and Endoplasmic Reticulum Stress in Chick Embryos
Guang Wang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Direct Activation of Bax Protein for Cancer Therapy
Zhiqing Liu et al.
MEDICINAL RESEARCH REVIEWS (2016)
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
Jiusheng Deng et al.
ONCOTARGET (2016)
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
Andrew W. Roberts et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Bingshe Han et al.
CANCER CELL (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R. Lavik et al.
ONCOTARGET (2015)
BH4 domain of Bcl-2 as a novel target for cancer therapy
Zhiqing Liu et al.
DRUG DISCOVERY TODAY (2015)
Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: Potential new target for cancer treatment
Edward F. Greenberg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum
Haidar Akl et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
Elham Fakhrejahani et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Antiangiogenic therapy in the management of breast cancer
Yuan Wu et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013)
Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer
Dongkyoo Park et al.
CANCER RESEARCH (2013)
Targeting the Bcl-2 family for cancer therapy
Shibu Thomas et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
Simone M. Schoenwaelder et al.
BLOOD (2011)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Angiogenesis and Breast Cancer
Adhemar Longatto Filho et al.
JOURNAL OF ONCOLOGY (2010)
Antiangiogenic therapy for breast cancer
Dorte Lisbet Nielsen et al.
BREAST CANCER RESEARCH (2010)
The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor
Yi-Ping Rong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737
Ozgur Kutuk et al.
CANCER RESEARCH (2008)
Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway
Qinhong Wang et al.
MOLECULAR CELL (2008)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Unidirectional crosstalk between Bcl-x(L) and Bcl-2 enhances the angiogenic phenotype of endothelial cells
E. Karl et al.
CELL DEATH AND DIFFERENTIATION (2007)
VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRβ signaling
MR Kano et al.
JOURNAL OF CELL SCIENCE (2005)
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines
E Karl et al.
CANCER RESEARCH (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
A mechanism for the proapoptotic activity of ursodeoxycholic acid: effects on Bcl-2 conformation
M Castelli et al.
CELL DEATH AND DIFFERENTIATION (2004)
Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay
MG Cattaneo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death
S Shimizu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
